A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan
- PMID: 29429413
- PMCID: PMC6389057
- DOI: 10.1186/s40249-018-0386-7
A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan
Abstract
Background: Approximately 10 million people in Pakistan are infected with the hepatitis C virus (HCV). Most patients develop chronic hepatitis, with rare cases of spontaneous clearance. However, little is known about multidrug resistant viral variants in Pakistan.
Findings: This case study describes a 47-year-old male diagnosed with chronic HCV genotype 3a infection in 2003. After an initial diagnosis of viral infection, the patient remained treatment naïve for 5 years. He received two therapy cycles of interferon (IFN) plus ribavirin (RBV) in 2007 and 2010, however, he was non-responsive to the therapy. The patient then received an additional two treatment cycles of pegylated IFN α-2b plus RBV (in 2011 and 2013); he was still non-responsive. In 2016, the patient underwent sofosbuvir plus RBV combination therapy, however, the sustained virological response was still not achieved. The host genetic factor was found to be heterozygous guanine and thymine (GT) and cytosine and thymine (CT) genotypes of rs8099917 and rs12979860 polymorphism of IL28B, respectively. Phylogenetic analysis suggests that the resistant variant belong to an out-group and may require triple therapy.
Conclusions: This is the first case that reports on a HCV-infected individual who was a non-responder to multiple IFN therapies in Pakistan. Further studies are needed to understand multidrug-resistant HCV variants in the Pakistani population.
Conflict of interest statement
Ethics approval and consent to participate
The study has been approved by the departmental ethical committee of Quaid-i-Azam University Islamabad under the number biotech-F-15-657. Informed consent was obtained from the patient before the blood samples were collected.
Consent for publication
Authors have obtained consent from the study participant to report the data without disclosing his identity.
Competing interests
The authors declare that they have no competing interests.
Figures


Similar articles
-
Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.Int J Infect Dis. 2015 Jan;30:91-7. doi: 10.1016/j.ijid.2014.09.021. Epub 2014 Nov 20. Int J Infect Dis. 2015. PMID: 25462177
-
Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.J Hepatol. 2012 Apr;56(4):788-94. doi: 10.1016/j.jhep.2011.11.008. Epub 2011 Dec 13. J Hepatol. 2012. PMID: 22173157
-
Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14. Liver Int. 2014. PMID: 24102823
-
Role of IL28B for chronic hepatitis C treatment toward personalized medicine.J Gastroenterol Hepatol. 2014 Feb;29(2):241-9. doi: 10.1111/jgh.12475. J Gastroenterol Hepatol. 2014. PMID: 24325405 Review.
-
IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.Rom J Intern Med. 2011;49(2):99-104. Rom J Intern Med. 2011. PMID: 22303600 Review.
Cited by
-
Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.Medicina (Kaunas). 2018 Nov 5;54(5):80. doi: 10.3390/medicina54050080. Medicina (Kaunas). 2018. PMID: 30400604 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous